Prognostic Value of KRAS/TP53 Status for Overall Survival in First-Line Monoimmunotherapy and Chemoimmunotherapy Treated Patients With Nonsquamous NSCLC in the Netherlands: A Brief Report
Among patients with metastatic NSCLC who are treated with pembrolizumab or chemoimmunotherapy, the presence of a pathogenic <i>TP53</i> and <i>KRAS</i> mutation is associated with longer OS. Nevertheless, in multivariable Cox regression analysis including age, sex, clinical disease stage, and PD-L1 tumor proportion score, <i>KRAS</i>/<i>TP53</i> mutation status was no longer associated with OS.
Authors
- Anthonie J. van der Wekken (ORCID: https://orcid.org/0000-0001-7175-0026)
- Léon C.L.T. van Kempen (ORCID: https://orcid.org/0000-0003-0646-0705)
- Betzabel N. Cajiao Garcia (ORCID: https://orcid.org/0000-0003-0233-5114)
- Vincent D. de Jager (ORCID: https://orcid.org/0009-0009-3539-8809)
- Stefan M. Willems (ORCID: https://orcid.org/0000-0001-7439-8216)
- T. Jeroen N. Hiltermann (ORCID: https://orcid.org/0000-0002-0665-2160)
- Ed Schuuring
Institutions
- University Medical Center Groningen (NL)
- University of Antwerp (BE)
- University of Groningen (NL)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1016/j.jtocrr.2024.100745
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- Eli Lilly and Company
- Pfizer
- Bayer
- Roche
- AstraZeneca Korea
- Merck Sharp and Dohme